Classifying Oropharyngeal Cancer by p16 Status Alone Deemed Insufficient
Oropharyngeal cancer patients who have discordant p16 and HPV status have worse prognosis than patients who have p16+/HPV+ disease, a study suggests.
Oropharyngeal cancer patients who have discordant p16 and HPV status have worse prognosis than patients who have p16+/HPV+ disease, a study suggests.
Non-Hispanic White men are less likely to die from HPV-related oropharyngeal cancer, when compared with Hispanic and non-Hispanic Black men.
Reducing the radiotherapy dose and target volume to subclinical regions produced “favorable clinical outcomes,” according to researchers.
The incidence of oropharyngeal cancer in men increased 2.7% per year.
Under a status quo scenario based on current levels of HPV vaccination, 792,000 OPC cases in men would be prevented by the year 2100.
The 2-year progression-free survival rate exceeded 90% for all treatment arms.
Findings suggest a need for tailored treatment in oropharyngeal squamous cell carcinoma.
Investigators tested the efficacy of reduced-dose radiation plus cisplatin in patients with good-risk human papillomavirus–associated oropharyngeal squamous cell carcinoma (OPSCC).
This analysis identified the factors for poor long-term survival in radiotherapy (RT)-treated patients with oropharyngeal cancer (OPC).
Outcomes and survival improved for early-stage oropharyngeal cancer, but not other cancers.